
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is poised for success with its promising pipeline, particularly the company's lead candidate PBFT02, which targets the critical underlying pathology of neurodegenerative diseases. However, regulatory hurdles may pose a challenge for the company, as evidenced by Eli Lilly's discontinuation of a similar program earlier this year due to a lack of efficacy in patients. As such, investors should closely monitor the company's advancements in clinical trials and regulatory approvals.
Bears say
Passage Bio is a clinical-stage company with limited revenue from licensing and royalties and only $46.3 million in cash at the end of FY25, which may not be enough to support their gene therapy development and commercialization efforts. Additionally, there are clinical and competitive risks that may hinder the success of their lead program PBFT02 for frontotemporal dementia, as well as the standard risks in the biotech industry. These factors, combined with the overall uncertain future of gene therapy, contribute to a negative outlook on Passage Bio's stock.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares